Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 7/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22830086 | 0.89 | HTT (0.40) | HTTEPHX2KMT2AACHEALDH1A1 | |
| SCHEMBL22886904 | 0.81 | HTT (0.36) | HTTEPHX2KMT2AACHEALDH1A1 | |
| SCHEMBL22886905 | 0.80 | LMNA (0.40) | HTTEPHX2KMT2AACHEALDH1A1 | |
| SCHEMBL29773453 | 0.77 | EPHX2 (0.56) | HTTPRMT1EPHX2KMT2AADRA1A | |
| SCHEMBL15550570 | 0.77 | HTT (0.56) | HTTPRMT1EPHX2KMT2AACHE | |
| SCHEMBL15549930 | 0.77 | HTT (0.56) | HTTPRMT1EPHX2ACHEADRA1A | |
| SCHEMBL22830261 | 0.76 | EGLN1 (0.39) | ALDH1A1LMNAATM | |
| SCHEMBL22886880 | 0.75 | CHRNB2 (0.41) | HTTKMT2AACHEALDH1A1LMNA | |
| SCHEMBL15550569 | 0.74 | HTT (0.53) | HTTEPHX2ACHE | |
| SCHEMBL15551259 | 0.74 | ACHE (0.63) | HTTEPHX2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115976028-B | Glycogen disease type Ia therapeutic agent | 第一三共株式会社 | 2025-03-25 | — | — | CN | disclosed |
| CN-119326905-A | GalNAc-oligonucleotide conjugate for delivery to liver and preparation method thereof | 第一三共株式会社 | 2025-01-21 | — | — | CN | disclosed |
| CN-114616332-B | GalNAc-oligonucleotide conjugate for delivery to liver and preparation method thereof | 第一三共株式会社 | 2024-09-20 | — | — | CN | disclosed |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-01 | — | — | US | disclosed |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-01 | — | — | US | disclosed |
| EP-4029520-A1 | GALNAC-OLIGONUCLEOTIDE CONJUGATE FOR LIVER-TARGETED DELIVERY USE, AND METHOD FOR PRODUCING SAME | Daiichi Sankyo Company, Limited (JP) | 2022-07-20 | — | — | EP | disclosed |
| CN-114616332-A | GalNAc-oligonucleotide conjugates for delivery to liver and methods of making the same | 第一三共株式会社 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021049504-A1 | GALNAC-OLIGONUCLEOTIDE CONJUGATE FOR LIVER-TARGETED DELIVERY USE, AND METHOD FOR PRODUCING SAME | 第一三共株式会社 | 2021-03-18 | — | — | WO | disclosed |
| EP-3763815-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | Daiichi Sankyo Company, Limited (JP) | 2021-01-13 | — | — | EP | disclosed |
| EP-3763815-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | Daiichi Sankyo Company, Limited (JP) | 2021-01-13 | — | — | EP | disclosed |
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-31 | — | — | US | disclosed |
| WO-2019172286-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | 第一三共株式会社 | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407394-A1 | THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA | G6PC1, GAA, GBA3 | HTT 583/4885PRMT1 4734/4885EPHX2 3916/4885 |
| US-11958878-B2 | Therapeutic agent for glycogen storage disease type IA | G6PC1, GAA, GBA3 | HTT 598/4885PRMT1 4756/4885EPHX2 3941/4885 |
| US-20220378920-A1 | CONJUGATE OF GalNAc-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF | CSGALNACT1, GALNT6, GALNT14 | HTT 3231/4885PRMT1 4506/4885EPHX2 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.